An 83-year-old man presented to our hospital with severe nausea, vomiting, and anorexia lasting more than 2 weeks. He had a medical history of left sole resection for melanoma 7 years earlier. He had lymph node recurrence in the left thigh and had initially been treated with pembrolizumab the previous year. After eight cycles of this immunotherapy, lung metastasis was observed by computed tomography (CT). He was then administrated second-line combo-therapy with ipilimumab and nivolumab and complained of appetite loss 2 weeks after the administration. On his admission, no notable changes were observed on laboratory examinations or CT. Esophagogastroduodenoscopy (EGD) revealed erythematous and edematous mucosa with purulent discharge in the gastric body and shallow, network-like erosion in the antrum (Fig. 1a,b). The gastric mucosa was extremely fragile. A biopsy specimen showed epithalaxia at the surface and severe inflammatory cell infiltration in the lamina propria (Fig. 2a). Helicobacter pylori infection was not found by a histological analysis or serological examination. This patient was diagnosed with immune checkpoint inhibitor (ICI)-related gastritis based on the endoscopic and the histological examination findings. Immunohistochemically, the infiltrating lymphocytes were positive for CD8 (Fig. 2b). He was administered 40 mg of prednisolone (PSL), and his symptoms remarkably improved starting a few days after administration. EGD at 2 weeks after the initiation of PSL revealed improvement in his gastritis, and the erosion and fragility of the mucosa were also healed (Fig. 1c). The histopathological findings showed a decrease in inflammatory cell infiltration and recovery of the foveolar epithelium and the proper glands.
Figure 1. Endoscopic findings of immune checkpoint inhibitor-related gastritis. (a) Erythematous and edematous gastric mucosa were shown in the gastric body. (b) Shallow network-like erosion in the antrum resembles spider webs. (c) Endoscopic findings after the treatment. The gastric erosion and fragility of the mucosa are improved 2 weeks after the administration of prednisolone.
Figure 2. The histological findings of gastritis. (a) A biopsy specimen shows epithalaxia at the surface and severe inflammatory cell infiltration in the lamina propria (HE, 100×). (b) Immunohistochemical staining of the biopsy specimen. The infiltrating lymphocytes were positive for CD8 (200×).
ICIs have dramatically changed cancer treatment. However, while the efficacy of ICIs has been proven for various solid cancers, many immune-related adverse events (irAEs) caused by ICI have been reported. IrAEs can be developed in many organs, including the gastrointestinal tract, endocrine organs, joints and skin, and nervous system.1 Colitis is frequently noted, but gastritis is rarely reported.2 The clinical symptoms suspecting ICI-related gastritis include nausea, vomiting, abdominal pain (epigastric pain), loss of appetite, and weight loss. EGD should be performed when ICI-related gastritis is suspected. Endoscopically, erythematous and edematous mucosa is mainly observed, and mucosal fragility and white fibrin-like membranes (spiderweb-like appearance) are characteristically found. Histologically, a combination of diffuse, moderate-to-severe active chronic gastritis with intra-epithelial lymphocytosis and increased apoptotic activity is the most helpful feature for diagnosing ICI-related gastritis.3 The histological finding of exfoliated epithelial cells corresponds to the mucosal fragility and shallow erosion observed by EGD. As it is sometimes difficult to determine the causes of these gastrointestinal symptoms, an endoscopic examination may be useful for clarifying the etiology.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Abstract
The histological findings of gastritis. (a) A biopsy specimen shows epithalaxia at the surface and severe inflammatory cell infiltration in the lamina propria (HE, 100×). (b) Immunohistochemical staining of the biopsy specimen. IrAEs can be developed in many organs, including the gastrointestinal tract, endocrine organs, joints and skin, and nervous system. 1 Colitis is frequently noted, but gastritis is rarely reported. 2 The clinical symptoms suspecting ICI-related gastritis include nausea, vomiting, abdominal pain (epigastric pain), loss of appetite, and weight loss. Histologically, a combination of diffuse, moderate-to-severe active chronic gastritis with intra-epithelial lymphocytosis and increased apoptotic activity is the most helpful feature for diagnosing ICI-related gastritis. 3 The histological finding of exfoliated epithelial cells corresponds to the mucosal fragility and shallow erosion observed by EGD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer